Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric L Simpson

Showing results (261-270 of 315) with videos related to

Pageof 32
Sort By:
JAMA Dermatology|April 19, 2023
Efficacy and Safety of Tralokinumab in Adolescents With Moderate to Severe Atopic Dermatitis: The Phase 3 ECZTRA 6 Randomized Clinical TrialAmy S Paller, Carsten Flohr, Michael Cork, et al.
Dermatology and Therapy|June 2, 2025
Rapid Itch Improvement and Skin Clearance with Upadacitinib Versus Placebo (Measure Up 1 and Measure Up 2) and Versus Dupilumab (Heads Up): Results from Three Phase 3 Clinical Trials in Patients with Moderate-to-Severe Atopic DermatitisEric L Simpson, Jonathan I Silverberg, Vimal H Prajapati, et al.
American Journal of Clinical Dermatology|May 9, 2019
Infections in Dupilumab Clinical Trials in Atopic Dermatitis: A Comprehensive Pooled AnalysisLawrence F Eichenfield, Thomas Bieber, Lisa A Beck, et al.
Journal of the American Academy of Dermatology|August 20, 2021
Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trialAndrew Blauvelt, Jonathan I Silverberg, Charles W Lynde, et al.
Clinical Pharmacology and Therapeutics|July 16, 2021
The Posology of Dupilumab in Pediatric Patients With Atopic DermatitisMohamed A Kamal, Pavel Kovalenko, Matthew P Kosloski, et al.
Journal of the American Academy of Dermatology|June 5, 2019
Patient-reported outcomes of adalimumab, phototherapy, and placebo in the Vascular Inflammation in Psoriasis Trial: A randomized controlled studyMegan H Noe, Marilyn T Wan, Daniel B Shin, et al.
Immunotherapy|November 15, 2021
Comparing abrocitinib and dupilumab in the treatment of atopic dermatitis: a plain language summaryThomas Bieber, Eric L Simpson, Jonathan I Silverberg, et al.
The New England Journal of Medicine|March 24, 2021
Abrocitinib versus Placebo or Dupilumab for Atopic DermatitisThomas Bieber, Eric L Simpson, Jonathan I Silverberg, et al.
Pharmaceutical Research|December 11, 2023
Integrated Exposure-Response of Dupilumab in Children, Adolescents, and Adults With Atopic Dermatitis Using Categorical and Continuous Efficacy Assessments: A Population AnalysisEmily Briggs, Mohamed A Kamal, Matthew P Kosloski, et al.
Journal of the American Academy of Dermatology|February 18, 2021
Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5)Eric L Simpson, Seth Forman, Jonathan I Silverberg, et al.
Pageof 32

Showing results (261-270 of 315) with videos related to

Sort By:
Pageof 32
JAMA Dermatology|April 19, 2023
Efficacy and Safety of Tralokinumab in Adolescents With Moderate to Severe Atopic Dermatitis: The Phase 3 ECZTRA 6 Randomized Clinical TrialAmy S Paller, Carsten Flohr, Michael Cork, et al.
Dermatology and Therapy|June 2, 2025
Rapid Itch Improvement and Skin Clearance with Upadacitinib Versus Placebo (Measure Up 1 and Measure Up 2) and Versus Dupilumab (Heads Up): Results from Three Phase 3 Clinical Trials in Patients with Moderate-to-Severe Atopic DermatitisEric L Simpson, Jonathan I Silverberg, Vimal H Prajapati, et al.
American Journal of Clinical Dermatology|May 9, 2019
Infections in Dupilumab Clinical Trials in Atopic Dermatitis: A Comprehensive Pooled AnalysisLawrence F Eichenfield, Thomas Bieber, Lisa A Beck, et al.
Journal of the American Academy of Dermatology|August 20, 2021
Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trialAndrew Blauvelt, Jonathan I Silverberg, Charles W Lynde, et al.
Clinical Pharmacology and Therapeutics|July 16, 2021
The Posology of Dupilumab in Pediatric Patients With Atopic DermatitisMohamed A Kamal, Pavel Kovalenko, Matthew P Kosloski, et al.
Journal of the American Academy of Dermatology|June 5, 2019
Patient-reported outcomes of adalimumab, phototherapy, and placebo in the Vascular Inflammation in Psoriasis Trial: A randomized controlled studyMegan H Noe, Marilyn T Wan, Daniel B Shin, et al.
Immunotherapy|November 15, 2021
Comparing abrocitinib and dupilumab in the treatment of atopic dermatitis: a plain language summaryThomas Bieber, Eric L Simpson, Jonathan I Silverberg, et al.
The New England Journal of Medicine|March 24, 2021
Abrocitinib versus Placebo or Dupilumab for Atopic DermatitisThomas Bieber, Eric L Simpson, Jonathan I Silverberg, et al.
Pharmaceutical Research|December 11, 2023
Integrated Exposure-Response of Dupilumab in Children, Adolescents, and Adults With Atopic Dermatitis Using Categorical and Continuous Efficacy Assessments: A Population AnalysisEmily Briggs, Mohamed A Kamal, Matthew P Kosloski, et al.
Journal of the American Academy of Dermatology|February 18, 2021
Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5)Eric L Simpson, Seth Forman, Jonathan I Silverberg, et al.
Pageof 32